We are excited to report that Lenz Therapeutics has officially submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for LNZ100, an aceclidine-based ophthalmic solution designed to treat presbyopia. As a condition affecting more than 128 million people in the United States and an estimated 1.8 billion globally, presbyopia remains a critical focus in eye care. The submission of this NDA is a significant milestone for Lenz, reflecting years of dedication, innovation, and clinical research.

If approved, LNZ100 would become the third FDA-approved eye drop for presbyopia, joining Vuity (approved in 2021) and Qlosi (approved in 2023). The FDA now has 60 days to determine whether the submission is complete and acceptable for review. 

At Presbyopia Physician, we are honored to have been following Lenz Therapeutics’ journey,^1-3 along with other developments in the rapidly expanding presbyopia treatment landscape.

In this issue, we delve deeper into the implications of LNZ100’s potential approval. Dr. McCabe provides a comprehensive analysis of Brimochol PF, as well as a second article discussing the importance of educating both patients and staff. Her insights are particularly valuable in light of the ongoing expansion of treatment options for presbyopia, and she highlights how programs such as Alcon’s Accelerator can enhance the educational process for doctors, patients, and staff.

This edition also features a timely cover story on traumatic brain injuries (TBIs) and their impact on the accommodative system, especially as the summer Olympics have brought renewed attention to sports-related injuries. Dr. Jacqueline Theis, a recognized expert in this field, offers an in-depth examination of how TBIs affect ocular function, providing readers with a better understanding of the complexities involved.

Additionally, Dr. Kading explores the evolving role of artificial intelligence in eye care, discussing its potential to revolutionize practice management and patient care; Dr. Crowley looks at next steps for fitting patients with presbyopia-correcting contact lenses; and Paul Becker contributes a detailed discussion of lens technologies for early presbyopes, offering practical insights for practitioners. Finally, Dr. William Trattler’s “Case Corner” focuses on the challenges and “no-gos” of multifocal intraocular lenses, providing essential guidance for clinicians.

We hope that this edition of Presbyopia Physician inspires you to expand your knowledge and explore the growing possibilities in presbyopia care. The landscape is evolving rapidly, and staying informed is key to providing the best care for your patients. 

Jacob Lang, OD, is the lead optometrist at Associated Eye Care in Minnesota and is the director of the practice’s ocular disease residency program. He specializes in cornea and ocular surface diseases, as well as therapeutic contact lenses and surgical comanagement. He is also adjunct clinical faculty at the Illinois College of Optometry, The Ohio State University, and Salus University.

Jennifer Loh, MD, is a board-certified ophthalmologist practicing in Miami, with a focus on cataract-refractive surgery and dry eye disease. She is founder and medical director of her practice, Loh Ophthalmology Associates, which she started in 2016. Dr. Loh also spends her time as a clinical and surgical attending physician for the Larkin Hospital Ophthalmology Residency program. She is a graduate of Indiana University School of Medicine, where she completed both medical school and ophthalmology residency.